b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29559562</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>19</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>19</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Print">1078-0432</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>24</Volume>\n                    <Issue>13</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>07</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>\n                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Adjuvant Treatment for <i>POLE</i> Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>3197-3203</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-18-0266</ELocationID>\n            <Abstract>\n                <AbstractText><b>Purpose:</b> Pathogenic <i>POLE</i> proofreading domain mutations are found in many malignancies where they are associated with ultramutation and favorable prognosis. The extent to which this prognosis depends on their sensitivity to adjuvant treatment is unknown, as is the optimal therapy for advanced-staged or recurrent <i>POLE</i>-mutant cancers.<b>Experimental Design:</b> We examined the recurrence-free survival of women with <i>POLE</i>-mutant and <i>POLE-</i>wild-type endometrial cancers (EC) in the observation arm of the randomized PORTEC-1 endometrial cancer trial (<i>N</i> = 245 patients with stage I endometrial cancer for analysis). Sensitivity to radiotherapy and selected chemotherapeutics was compared between <i>Pole</i>-mutant mouse-derived embryonic stem (mES) cells, generated using CRISPR-Cas9 (<i>Pole</i> mutations D275A/E275A, and cancer-associated P286R, S297F, V411L) and isogenic wild-type cell lines.<b>Results:</b> In the observation arm of the PORTEC-1 trial (<i>N</i> = 245), women with <i>POLE</i>-mutant endometrial cancers (<i>N</i> = 16) had an improved recurrence-free survival (10-year recurrence-free survival 100% vs. 80.1% for <i>POLE-</i>wild-type; HR, 0.143; 95% confidence interval, 0.001-0.996; <i>P</i> = 0.049). <i>Pole</i> mutations did not increase sensitivity to radiotherapy nor to chemotherapeutics in mES cells. In contrast, <i>Pole</i>-mutant cells displayed significantly increased sensitivity to cytarabine and fludarabine (IC<sub>50</sub><i>Pole</i> P286R-mutant vs. wild-type: 0.05 vs. 0.17 \xce\xbcmol/L for cytarabine, 4.62 vs. 11.1 \xce\xbcmol/L for fludarabine; <i>P</i> &lt; 0.001 for both comparisons).<b>Conclusions:</b> The favorable prognosis of <i>POLE</i>-mutant cancers cannot be explained by increased sensitivity to currently used adjuvant treatments. These results support studies exploring minimization of adjuvant therapy for early-stage <i>POLE</i>-mutant cancers, including endometrial and colorectal cancers. Conversely, <i>POLE</i> mutations result in hypersensitivity to nucleoside analogues, suggesting the use of these compounds as a potentially effective targeted treatment for advanced-stage <i>POLE</i>-mutant cancers. <i>Clin Cancer Res; 24(13); 3197-203. \xc2\xa92018 AACR</i>.</AbstractText>\n                <CopyrightInformation>\xc2\xa92018 American Association for Cancer Research.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Van Gool</LastName>\n                    <ForeName>Inge C</ForeName>\n                    <Initials>IC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rayner</LastName>\n                    <ForeName>Emily</ForeName>\n                    <Initials>E</Initials>\n                    <Identifier Source="ORCID">0000-0002-0477-9408</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Molecular and Population Genetics Laboratory, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Osse</LastName>\n                    <ForeName>Elisabeth M</ForeName>\n                    <Initials>EM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nout</LastName>\n                    <ForeName>Remi A</ForeName>\n                    <Initials>RA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical and Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Creutzberg</LastName>\n                    <ForeName>Carien L</ForeName>\n                    <Initials>CL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical and Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tomlinson</LastName>\n                    <ForeName>Ian P M</ForeName>\n                    <Initials>IPM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Molecular and Population Genetics Laboratory, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Church</LastName>\n                    <ForeName>David N</ForeName>\n                    <Initials>DN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Molecular and Population Genetics Laboratory, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Oxford Cancer Centre, Churchill Hospital, Oxford, United Kingdom.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Smit</LastName>\n                    <ForeName>Vincent T H B M</ForeName>\n                    <Initials>VTHBM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>de Wind</LastName>\n                    <ForeName>Niels</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands. T.Bosse@lumc.nl N.de_Wind@lumc.nl.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bosse</LastName>\n                    <ForeName>Tjalling</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. T.Bosse@lumc.nl N.de_Wind@lumc.nl.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Drost</LastName>\n                    <ForeName>Mark</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <Acronym>DH_</Acronym>\n                    <Agency>Department of Health</Agency>\n                    <Country>United Kingdom</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>090532/Z/09/Z</GrantID>\n                    <Acronym>WT_</Acronym>\n                    <Agency>Wellcome Trust</Agency>\n                    <Country>United Kingdom</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>03</Month>\n                <Day>20</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Clin Cancer Res</MedlineTA>\n            <NlmUniqueID>9502500</NlmUniqueID>\n            <ISSNLinking>1078-0432</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000075223">Poly-ADP-Ribose Binding Proteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.7.-</RegistryNumber>\n                <NameOfSubstance UI="D004257">DNA Polymerase II</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.7.7</RegistryNumber>\n                <NameOfSubstance UI="C119525">POLE protein, human</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004257" MajorTopicYN="N">DNA Polymerase II</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000075223" MajorTopicYN="N">Poly-ADP-Ribose Binding Proteins</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>01</Month>\n                <Day>23</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>02</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>03</Month>\n                <Day>14</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29559562</ArticleId>\n            <ArticleId IdType="pii">1078-0432.CCR-18-0266</ArticleId>\n            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-0266</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'